SPDR S&P Biotech (XBI) Shares Bought by Cumberland Advisors Inc.

Cumberland Advisors Inc. boosted its position in shares of SPDR S&P Biotech (NYSEARCA:XBI) by 916.1% during the fourth quarter, HoldingsChannel reports. The firm owned 41,660 shares of the exchange traded fund’s stock after buying an additional 37,560 shares during the quarter. SPDR S&P Biotech comprises approximately 2.0% of Cumberland Advisors Inc.’s holdings, making the stock its 23rd biggest position. Cumberland Advisors Inc.’s holdings in SPDR S&P Biotech were worth $3,536,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the company. Quantitative Investment Management LLC lifted its position in shares of SPDR S&P Biotech by 642.3% in the second quarter. Quantitative Investment Management LLC now owns 1,451,998 shares of the exchange traded fund’s stock valued at $112,065,000 after acquiring an additional 1,256,398 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of SPDR S&P Biotech by 2.7% in the third quarter. Wells Fargo & Company MN now owns 1,449,462 shares of the exchange traded fund’s stock valued at $125,480,000 after acquiring an additional 38,545 shares in the last quarter. Assetmark Inc. lifted its position in shares of SPDR S&P Biotech by 59.9% in the third quarter. Assetmark Inc. now owns 1,239,051 shares of the exchange traded fund’s stock valued at $107,265,000 after acquiring an additional 464,246 shares in the last quarter. First Republic Investment Management Inc. lifted its position in shares of SPDR S&P Biotech by 7.9% in the third quarter. First Republic Investment Management Inc. now owns 408,745 shares of the exchange traded fund’s stock valued at $35,385,000 after acquiring an additional 29,852 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of SPDR S&P Biotech by 162.8% in the third quarter. SG Americas Securities LLC now owns 303,622 shares of the exchange traded fund’s stock valued at $26,285,000 after acquiring an additional 188,106 shares in the last quarter.

Shares of SPDR S&P Biotech (NYSEARCA XBI) traded up $1.21 during trading hours on Tuesday, hitting $86.52. The stock had a trading volume of 5,894,800 shares, compared to its average volume of 5,044,740. SPDR S&P Biotech has a twelve month low of $61.14 and a twelve month high of $88.98. The stock has a market capitalization of $4,570.00 and a P/E ratio of 4.75.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 26th. Stockholders of record on Monday, December 18th were given a $0.0347 dividend. The ex-dividend date of this dividend was Friday, December 15th. This represents a $0.14 annualized dividend and a dividend yield of 0.16%. SPDR S&P Biotech’s dividend payout ratio is currently 1.10%.

ILLEGAL ACTIVITY WARNING: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2018/01/09/spdr-sp-biotech-xbi-shares-bought-by-cumberland-advisors-inc.html.

SPDR S&P Biotech Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

What are top analysts saying about SPDR S&P Biotech? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for SPDR S&P Biotech and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit